Share Price and Basic Stock Data
Last Updated: January 7, 2026, 10:25 am
| PEG Ratio | 3.18 |
|---|
Analyst Insight & Comprehensive Analysis
AI Stock Ranker – Real-Time Fundamental Strength Score
Business Overview and Revenue Trends
Sharda Cropchem Ltd operates in the agrochemicals and pesticides sector, which has shown a robust performance over recent years. The company’s market capitalization is ₹7,482 Cr, and it reported a price of ₹830 per share. Revenue from operations for the fiscal year ending March 2023 stood at ₹4,045 Cr, reflecting a significant increase from ₹3,580 Cr in the previous fiscal year. The trailing twelve months (TTM) revenue reached ₹4,672 Cr, indicating continuous growth in sales. The quarterly sales figures reveal fluctuations, with the highest quarterly revenue of ₹1,482 Cr recorded in March 2023, followed by a decline to ₹581 Cr in September 2023. This decline may raise concerns about seasonal impacts or market volatility. However, the company’s overall growth trajectory appears positive, bolstered by a diversified product portfolio and strategic market positioning.
Profitability and Efficiency Metrics
Sharda Cropchem has demonstrated solid profitability metrics, with a reported net profit of ₹452 Cr, yielding a P/E ratio of 16.6 and a return on equity (ROE) of 12.6%. The operating profit margin (OPM) averaged 14% for the fiscal year ending March 2025, although it faced challenges with a negative OPM of -9% in June 2023. The company has been efficient in managing expenses, with total expenses recorded at ₹3,386 Cr for March 2023, which is lower than the revenue growth. The interest coverage ratio (ICR) stood at an impressive 311.10x, indicating a strong ability to meet interest obligations. However, the operating profit has shown volatility, and the company must stabilize its margins to ensure consistent profitability. The cash conversion cycle (CCC) of 124 days reflects reasonable efficiency in managing working capital, though improvements could enhance liquidity.
Balance Sheet Strength and Financial Ratios
The balance sheet of Sharda Cropchem reveals a strong financial position, with total assets amounting to ₹4,713 Cr and negligible borrowings of merely ₹4 Cr. This low debt level supports a healthy leverage ratio and reduces financial risk. The reserves have grown to ₹2,585 Cr as of September 2025, showcasing the company’s ability to reinvest profits effectively. The price-to-book value (P/BV) ratio of 2.06x indicates that the stock is trading at a premium relative to its book value, which may suggest investor confidence in future growth prospects. The current ratio stands at 1.81, indicating good short-term liquidity. However, the decline in return on capital employed (ROCE) to 16% for March 2025 from previous highs suggests potential inefficiencies or suboptimal asset utilization that the management may need to address.
Shareholding Pattern and Investor Confidence
Sharda Cropchem’s shareholding structure reflects a strong commitment from promoters, holding 74.82% of the company, which indicates stability and control. Foreign Institutional Investors (FIIs) have gradually increased their stake from 2.41% in December 2022 to 5.26% by September 2025, showing growing confidence among foreign investors. Domestic Institutional Investors (DIIs) have maintained a steady presence, holding 9.26% of shares as of September 2025. The number of shareholders reached 67,290, indicating increasing retail participation. However, the decline in DIIs from a peak of 12.61% in December 2022 to 9.26% raises some concerns about institutional support. Overall, the strong promoter holding combined with increasing FII participation may reinforce investor confidence, potentially stabilizing the stock price amidst market fluctuations.
Outlook, Risks, and Final Insight
The outlook for Sharda Cropchem appears cautiously optimistic, bolstered by its strong market position and financial metrics. Continued growth in revenue and profitability, coupled with robust liquidity, are strengths that could drive future performance. However, the company faces risks such as market volatility, seasonality in sales, and the need to stabilize operating margins. Additionally, fluctuations in raw material prices and regulatory changes in the agrochemical industry could impact profitability. If Sharda Cropchem can effectively manage these risks and improve operational efficiencies, it may enhance its market standing. Conversely, failure to address profitability volatility or manage growth sustainably could lead to investor skepticism. The company’s ability to adapt and innovate in response to market conditions will be crucial for its long-term success.
Source: Getaka Fundamental Analysis | Generated using proprietary financial data.
Competitors
| Stock Name ⇩ | Market Cap ⇩ | Current Price ⇩ | High / Low ⇩ | Stock P/E ⇩ | Book Value ⇩ | Dividend Yield ⇩ | ROCE ⇩ | ROE ⇩ | Face Value ⇩ |
|---|---|---|---|---|---|---|---|---|---|
| Epigral Ltd | 4,997 Cr. | 1,158 | 2,114/1,151 | 12.4 | 487 | 0.51 % | 24.9 % | 22.3 % | 10.0 |
| Dharmaj Crop Guard Ltd | 804 Cr. | 238 | 391/165 | 16.5 | 131 | 0.00 % | 12.0 % | 9.28 % | 10.0 |
| Bhaskar Agrochemicals Ltd | 61.3 Cr. | 118 | 149/56.6 | 11.0 | 40.0 | 0.00 % | 21.3 % | 24.7 % | 10.0 |
| Bhagiradha Chemicals & Industries Ltd | 2,926 Cr. | 226 | 331/198 | 110 | 54.9 | 0.07 % | 7.44 % | 4.91 % | 1.00 |
| Best Agrolife Ltd | 1,046 Cr. | 442 | 596/244 | 81.7 | 342 | 0.45 % | 12.9 % | 9.95 % | 10.0 |
| Industry Average | 11,190.60 Cr | 1,131.99 | 32.39 | 382.34 | 0.42% | 15.21% | 19.87% | 7.04 |
Quarterly Result
| Metric | Sep 2022 | Dec 2022 | Mar 2023 | Jun 2023 | Sep 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 722 | 1,017 | 1,482 | 638 | 581 | 632 | 1,312 | 785 | 777 | 929 | 1,829 | 985 | 929 |
| Expenses | 656 | 810 | 1,164 | 697 | 560 | 563 | 1,057 | 708 | 687 | 815 | 1,525 | 770 | 796 |
| Operating Profit | 65 | 207 | 318 | -59 | 21 | 69 | 255 | 77 | 90 | 115 | 303 | 215 | 133 |
| OPM % | 9% | 20% | 21% | -9% | 4% | 11% | 19% | 10% | 12% | 12% | 17% | 22% | 14% |
| Other Income | 10 | 3 | 7 | 26 | 24 | 12 | -2 | 19 | 25 | 1 | 25 | 32 | 29 |
| Interest | 0 | 1 | 2 | 1 | 5 | 1 | 0 | 1 | 0 | 0 | 0 | 1 | 0 |
| Depreciation | 60 | 65 | 68 | 70 | 74 | 69 | 54 | 65 | 69 | 69 | 72 | 78 | 76 |
| Profit before tax | 15 | 143 | 255 | -105 | -34 | 12 | 198 | 31 | 46 | 46 | 256 | 169 | 86 |
| Tax % | 17% | 24% | 22% | -15% | -18% | 62% | 28% | 11% | 7% | 32% | 20% | 16% | 13% |
| Net Profit | 12 | 108 | 199 | -89 | -28 | 5 | 143 | 27 | 42 | 31 | 204 | 143 | 74 |
| EPS in Rs | 1.34 | 12.01 | 22.04 | -9.82 | -3.06 | 0.51 | 15.90 | 3.02 | 4.70 | 3.45 | 22.56 | 15.83 | 8.24 |
Last Updated: December 29, 2025, 5:00 am
Below is a detailed analysis of the quarterly data for Sharda Cropchem Ltd based on the most recent figures (Sep 2025) and their trends compared to the previous period:
- For Sales, as of Sep 2025, the value is 929.00 Cr.. The value appears to be declining and may need further review. It has decreased from 985.00 Cr. (Jun 2025) to 929.00 Cr., marking a decrease of 56.00 Cr..
- For Expenses, as of Sep 2025, the value is 796.00 Cr.. The value appears to be increasing, which may not be favorable. It has increased from 770.00 Cr. (Jun 2025) to 796.00 Cr., marking an increase of 26.00 Cr..
- For Operating Profit, as of Sep 2025, the value is 133.00 Cr.. The value appears to be declining and may need further review. It has decreased from 215.00 Cr. (Jun 2025) to 133.00 Cr., marking a decrease of 82.00 Cr..
- For OPM %, as of Sep 2025, the value is 14.00%. The value appears to be declining and may need further review. It has decreased from 22.00% (Jun 2025) to 14.00%, marking a decrease of 8.00%.
- For Other Income, as of Sep 2025, the value is 29.00 Cr.. The value appears to be declining and may need further review. It has decreased from 32.00 Cr. (Jun 2025) to 29.00 Cr., marking a decrease of 3.00 Cr..
- For Interest, as of Sep 2025, the value is 0.00 Cr.. The value appears to be improving (decreasing) as expected. It has decreased from 1.00 Cr. (Jun 2025) to 0.00 Cr., marking a decrease of 1.00 Cr..
- For Depreciation, as of Sep 2025, the value is 76.00 Cr.. The value appears to be improving (decreasing) as expected. It has decreased from 78.00 Cr. (Jun 2025) to 76.00 Cr., marking a decrease of 2.00 Cr..
- For Profit before tax, as of Sep 2025, the value is 86.00 Cr.. The value appears to be declining and may need further review. It has decreased from 169.00 Cr. (Jun 2025) to 86.00 Cr., marking a decrease of 83.00 Cr..
- For Tax %, as of Sep 2025, the value is 13.00%. The value appears to be improving (decreasing) as expected. It has decreased from 16.00% (Jun 2025) to 13.00%, marking a decrease of 3.00%.
- For Net Profit, as of Sep 2025, the value is 74.00 Cr.. The value appears to be declining and may need further review. It has decreased from 143.00 Cr. (Jun 2025) to 74.00 Cr., marking a decrease of 69.00 Cr..
- For EPS in Rs, as of Sep 2025, the value is 8.24. The value appears to be declining and may need further review. It has decreased from 15.83 (Jun 2025) to 8.24, marking a decrease of 7.59.
Overall, while many items appear to show a positive trend, any significant downward movement warrant further investigation.
Profit & Loss - Annual Report
Last Updated: December 15, 2025, 4:40 am
| Metric | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 790 | 1,061 | 1,222 | 1,399 | 1,707 | 1,998 | 2,003 | 2,396 | 3,580 | 4,045 | 3,163 | 4,320 | 4,672 |
| Expenses | 630 | 878 | 941 | 1,075 | 1,343 | 1,621 | 1,653 | 1,945 | 2,884 | 3,386 | 2,860 | 3,705 | 3,906 |
| Operating Profit | 160 | 183 | 281 | 324 | 364 | 376 | 350 | 450 | 696 | 659 | 303 | 615 | 766 |
| OPM % | 20% | 17% | 23% | 23% | 21% | 19% | 17% | 19% | 19% | 16% | 10% | 14% | 16% |
| Other Income | 32 | 25 | 23 | 14 | 9 | -22 | -12 | 46 | 29 | 40 | 60 | 60 | 88 |
| Interest | 8 | 9 | 8 | 9 | 15 | 20 | 16 | 16 | 15 | 20 | 24 | 21 | 2 |
| Depreciation | 29 | 23 | 35 | 56 | 70 | 99 | 137 | 170 | 245 | 248 | 267 | 275 | 295 |
| Profit before tax | 155 | 175 | 261 | 272 | 287 | 235 | 185 | 309 | 464 | 431 | 72 | 378 | 557 |
| Tax % | 29% | 30% | 33% | 30% | 34% | 25% | 11% | 26% | 25% | 21% | 56% | 20% | |
| Net Profit | 111 | 123 | 175 | 190 | 191 | 176 | 165 | 229 | 349 | 342 | 32 | 304 | 452 |
| EPS in Rs | 12.31 | 13.63 | 19.41 | 21.11 | 21.14 | 19.55 | 18.25 | 25.40 | 38.71 | 37.90 | 3.53 | 33.74 | 50.08 |
| Dividend Payout % | 16% | 18% | 21% | 19% | 19% | 20% | 22% | 20% | 16% | 16% | 85% | 27% |
YoY Net Profit Growth
| Year | 2014-2015 | 2015-2016 | 2016-2017 | 2017-2018 | 2018-2019 | 2019-2020 | 2020-2021 | 2021-2022 | 2022-2023 | 2023-2024 | 2024-2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| YoY Net Profit Growth (%) | 10.81% | 42.28% | 8.57% | 0.53% | -7.85% | -6.25% | 38.79% | 52.40% | -2.01% | -90.64% | 850.00% |
| Change in YoY Net Profit Growth (%) | 0.00% | 31.47% | -33.70% | -8.05% | -8.38% | 1.60% | 45.04% | 13.61% | -54.41% | -88.64% | 940.64% |
Sharda Cropchem Ltd has shown an inconsistent trend in YoY Net Profit Growth (%) in the last 11 years from 2014-2015 to 2024-2025.
Growth
| Compounded Sales Growth | |
|---|---|
| 10 Years: | 15% |
| 5 Years: | 17% |
| 3 Years: | 6% |
| TTM: | 37% |
| Compounded Profit Growth | |
|---|---|
| 10 Years: | 10% |
| 5 Years: | 8% |
| 3 Years: | -5% |
| TTM: | 184% |
| Stock Price CAGR | |
|---|---|
| 10 Years: | 12% |
| 5 Years: | 27% |
| 3 Years: | 21% |
| 1 Year: | 65% |
| Return on Equity | |
|---|---|
| 10 Years: | 15% |
| 5 Years: | 12% |
| 3 Years: | 10% |
| Last Year: | 13% |
Last Updated: September 5, 2025, 1:26 pm
Balance Sheet
Last Updated: December 4, 2025, 1:57 am
| Month | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Sep 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Equity Capital | 90 | 90 | 90 | 90 | 90 | 90 | 90 | 90 | 90 | 90 | 90 | 90 | 90 |
| Reserves | 466 | 564 | 715 | 870 | 1,045 | 1,194 | 1,313 | 1,524 | 1,822 | 2,142 | 2,147 | 2,410 | 2,585 |
| Borrowings | 40 | 38 | 2 | 0 | 170 | 0 | 0 | 81 | 47 | 3 | 18 | 8 | 4 |
| Other Liabilities | 319 | 354 | 522 | 686 | 914 | 914 | 940 | 1,163 | 1,779 | 2,108 | 1,773 | 2,205 | 2,224 |
| Total Liabilities | 914 | 1,047 | 1,329 | 1,646 | 2,219 | 2,198 | 2,343 | 2,858 | 3,738 | 4,343 | 4,028 | 4,713 | 4,903 |
| Fixed Assets | 64 | 88 | 130 | 210 | 226 | 372 | 416 | 544 | 592 | 668 | 708 | 750 | 1,109 |
| CWIP | 133 | 149 | 210 | 232 | 360 | 220 | 161 | 131 | 212 | 204 | 283 | 291 | 0 |
| Investments | 174 | 95 | 90 | 61 | 22 | 212 | 116 | 83 | 134 | 32 | 159 | 294 | 555 |
| Other Assets | 542 | 715 | 899 | 1,143 | 1,611 | 1,394 | 1,650 | 2,099 | 2,800 | 3,439 | 2,878 | 3,377 | 3,240 |
| Total Assets | 914 | 1,047 | 1,329 | 1,646 | 2,219 | 2,198 | 2,343 | 2,858 | 3,738 | 4,343 | 4,028 | 4,713 | 4,903 |
Below is a detailed analysis of the balance sheet data for Sharda Cropchem Ltd based on the most recent figures (Sep 2025) and their trends compared to the previous period:
- For Equity Capital, as of Sep 2025, the value is 90.00 Cr.. The value remains steady. There is no change compared to the previous period (Mar 2025) which recorded 90.00 Cr..
- For Reserves, as of Sep 2025, the value is 2,585.00 Cr.. The value appears strong and on an upward trend. It has increased from 2,410.00 Cr. (Mar 2025) to 2,585.00 Cr., marking an increase of 175.00 Cr..
- For Borrowings, as of Sep 2025, the value is 4.00 Cr.. The value appears to be improving (decreasing). Additionally, since Reserves exceed Borrowings, this is considered a positive sign. It has decreased from 8.00 Cr. (Mar 2025) to 4.00 Cr., marking a decrease of 4.00 Cr..
- For Other Liabilities, as of Sep 2025, the value is 2,224.00 Cr.. The value appears to be increasing, which may not be favorable. It has increased from 2,205.00 Cr. (Mar 2025) to 2,224.00 Cr., marking an increase of 19.00 Cr..
- For Total Liabilities, as of Sep 2025, the value is 4,903.00 Cr.. The value appears to be increasing, which may not be favorable. It has increased from 4,713.00 Cr. (Mar 2025) to 4,903.00 Cr., marking an increase of 190.00 Cr..
- For Fixed Assets, as of Sep 2025, the value is 1,109.00 Cr.. The value appears strong and on an upward trend. It has increased from 750.00 Cr. (Mar 2025) to 1,109.00 Cr., marking an increase of 359.00 Cr..
- For CWIP, as of Sep 2025, the value is 0.00 Cr.. The value appears to be declining and may need further review. It has decreased from 291.00 Cr. (Mar 2025) to 0.00 Cr., marking a decrease of 291.00 Cr..
- For Investments, as of Sep 2025, the value is 555.00 Cr.. The value appears strong and on an upward trend. It has increased from 294.00 Cr. (Mar 2025) to 555.00 Cr., marking an increase of 261.00 Cr..
- For Other Assets, as of Sep 2025, the value is 3,240.00 Cr.. The value appears to be declining and may need further review. It has decreased from 3,377.00 Cr. (Mar 2025) to 3,240.00 Cr., marking a decrease of 137.00 Cr..
- For Total Assets, as of Sep 2025, the value is 4,903.00 Cr.. The value appears strong and on an upward trend. It has increased from 4,713.00 Cr. (Mar 2025) to 4,903.00 Cr., marking an increase of 190.00 Cr..
Notably, the Reserves (2,585.00 Cr.) exceed the Borrowings (4.00 Cr.), indicating a solid financial buffer.
Overall, while many items appear to show a positive trend, any significant downward movement or items where Borrowings exceed Reserves warrant further investigation.
Cash Flow
| Month | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
Free Cash Flow
| Month | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Free Cash Flow | 120.00 | 145.00 | 279.00 | 324.00 | 194.00 | 376.00 | 350.00 | 369.00 | 649.00 | 656.00 | 285.00 | 607.00 |
Free Cash Flow = Income Generated from Operational Activities - Borrowings - Capital Work in Progress (CWIP)
Consistent positive free cash flow is crucial for businesses as it indicates their ability to generate cash from their core operations. It provides financial flexibility, allowing companies to invest in growth opportunities, pay dividends to shareholders, reduce debt, and weather economic downturns more effectively.
Financial Efficiency Indicators
| Month | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Debtor Days | 185 | 156 | 185 | 175 | 191 | 148 | 180 | 177 | 157 | 165 | 173 | 165 |
| Inventory Days | 57 | 72 | 74 | 117 | 169 | 96 | 100 | 117 | 130 | 145 | 155 | 117 |
| Days Payable | 146 | 117 | 179 | 186 | 202 | 167 | 180 | 180 | 172 | 176 | 144 | 158 |
| Cash Conversion Cycle | 97 | 111 | 81 | 106 | 158 | 77 | 100 | 114 | 115 | 134 | 184 | 124 |
| Working Capital Days | 67 | 82 | 95 | 99 | 94 | 71 | 101 | 94 | 88 | 97 | 128 | 92 |
| ROCE % | 28% | 27% | 36% | 32% | 27% | 23% | 18% | 21% | 26% | 21% | 4% | 16% |
Mutual Fund Holdings
| Fund Name | No of Shares | AUM (%) | Amount Invested (Cr) | Previous Number of Shares | Previous Date | Percentage Change |
|---|---|---|---|---|---|---|
| HDFC Small Cap Fund | 5,406,610 | 1.23 | 466.4 | N/A | N/A | N/A |
| DSP Small Cap Fund | 1,750,000 | 0.89 | 150.96 | 3,587,791 | 2025-12-07 00:37:56 | -51.22% |
| HDFC Hybrid Equity Fund | 920,000 | 0.32 | 79.36 | 846,062 | 2025-12-15 00:39:12 | 8.74% |
| Bandhan Balanced Advantage Fund | 50,000 | 0.19 | 4.31 | N/A | N/A | N/A |
Key Financial Ratios
| Month | Mar 25 | Mar 24 | Mar 23 | Mar 22 | Mar 21 |
|---|---|---|---|---|---|
| FaceValue | 10.00 | 10.00 | 10.00 | 10.00 | 10.00 |
| Basic EPS (Rs.) | 33.74 | 3.53 | 37.90 | 38.71 | 25.40 |
| Diluted EPS (Rs.) | 33.74 | 3.53 | 37.90 | 38.71 | 25.40 |
| Cash EPS (Rs.) | 64.19 | 33.15 | 65.41 | 65.91 | 44.30 |
| Book Value[Excl.RevalReserv]/Share (Rs.) | 277.16 | 248.00 | 247.44 | 212.01 | 178.96 |
| Book Value[Incl.RevalReserv]/Share (Rs.) | 277.16 | 248.00 | 247.44 | 212.01 | 178.96 |
| Revenue From Operations / Share (Rs.) | 478.81 | 350.59 | 448.36 | 396.78 | 265.53 |
| PBDIT / Share (Rs.) | 72.61 | 37.98 | 75.74 | 78.89 | 53.50 |
| PBIT / Share (Rs.) | 42.17 | 8.37 | 48.24 | 51.70 | 34.61 |
| PBT / Share (Rs.) | 41.93 | 7.97 | 47.74 | 51.46 | 34.30 |
| Net Profit / Share (Rs.) | 33.74 | 3.54 | 37.91 | 38.71 | 25.41 |
| NP After MI And SOA / Share (Rs.) | 33.74 | 3.53 | 37.90 | 38.71 | 25.40 |
| PBDIT Margin (%) | 15.16 | 10.83 | 16.89 | 19.88 | 20.14 |
| PBIT Margin (%) | 8.80 | 2.38 | 10.75 | 13.03 | 13.03 |
| PBT Margin (%) | 8.75 | 2.27 | 10.64 | 12.96 | 12.91 |
| Net Profit Margin (%) | 7.04 | 1.00 | 8.45 | 9.75 | 9.56 |
| NP After MI And SOA Margin (%) | 7.04 | 1.00 | 8.45 | 9.75 | 9.56 |
| Return on Networth / Equity (%) | 12.17 | 1.42 | 15.32 | 18.26 | 14.19 |
| Return on Capital Employeed (%) | 13.88 | 3.07 | 18.28 | 22.73 | 18.10 |
| Return On Assets (%) | 6.44 | 0.78 | 7.85 | 9.33 | 8.00 |
| Total Debt / Equity (X) | 0.00 | 0.00 | 0.00 | 0.01 | 0.04 |
| Asset Turnover Ratio (%) | 0.98 | 0.75 | 0.85 | 0.93 | 0.80 |
| Current Ratio (X) | 1.81 | 1.86 | 1.65 | 1.69 | 1.84 |
| Quick Ratio (X) | 1.32 | 1.23 | 1.08 | 1.16 | 1.38 |
| Inventory Turnover Ratio (X) | 4.40 | 1.40 | 1.59 | 1.96 | 2.19 |
| Dividend Payout Ratio (NP) (%) | 18.16 | 85.75 | 16.21 | 15.49 | 7.87 |
| Dividend Payout Ratio (CP) (%) | 9.54 | 9.14 | 9.39 | 9.10 | 4.51 |
| Earning Retention Ratio (%) | 81.84 | 14.25 | 83.79 | 84.51 | 92.13 |
| Cash Earning Retention Ratio (%) | 90.46 | 90.86 | 90.61 | 90.90 | 95.49 |
| Interest Coverage Ratio (X) | 311.10 | 94.68 | 151.52 | 321.65 | 174.12 |
| Interest Coverage Ratio (Post Tax) (X) | 145.56 | 9.82 | 76.83 | 158.84 | 83.69 |
| Enterprise Value (Cr.) | 4929.40 | 2811.46 | 4234.14 | 5420.45 | 2398.75 |
| EV / Net Operating Revenue (X) | 1.14 | 0.88 | 1.05 | 1.51 | 1.00 |
| EV / EBITDA (X) | 7.52 | 8.21 | 6.20 | 7.62 | 4.97 |
| MarketCap / Net Operating Revenue (X) | 1.19 | 0.91 | 1.09 | 1.55 | 1.08 |
| Retention Ratios (%) | 81.83 | 14.24 | 83.78 | 84.50 | 92.12 |
| Price / BV (X) | 2.06 | 1.29 | 1.98 | 2.90 | 1.61 |
| Price / Net Operating Revenue (X) | 1.19 | 0.91 | 1.09 | 1.55 | 1.08 |
| EarningsYield | 0.05 | 0.01 | 0.07 | 0.06 | 0.08 |
After reviewing the key financial ratios for Sharda Cropchem Ltd, here is a detailed analysis based on the latest available data and recent trends:
- For FaceValue, as of Mar 25, the value is 10.00. This value is within the healthy range. There is no change compared to the previous period (Mar 24) which recorded 10.00.
- For Basic EPS (Rs.), as of Mar 25, the value is 33.74. This value is within the healthy range. It has increased from 3.53 (Mar 24) to 33.74, marking an increase of 30.21.
- For Diluted EPS (Rs.), as of Mar 25, the value is 33.74. This value is within the healthy range. It has increased from 3.53 (Mar 24) to 33.74, marking an increase of 30.21.
- For Cash EPS (Rs.), as of Mar 25, the value is 64.19. This value is within the healthy range. It has increased from 33.15 (Mar 24) to 64.19, marking an increase of 31.04.
- For Book Value[Excl.RevalReserv]/Share (Rs.), as of Mar 25, the value is 277.16. It has increased from 248.00 (Mar 24) to 277.16, marking an increase of 29.16.
- For Book Value[Incl.RevalReserv]/Share (Rs.), as of Mar 25, the value is 277.16. It has increased from 248.00 (Mar 24) to 277.16, marking an increase of 29.16.
- For Revenue From Operations / Share (Rs.), as of Mar 25, the value is 478.81. It has increased from 350.59 (Mar 24) to 478.81, marking an increase of 128.22.
- For PBDIT / Share (Rs.), as of Mar 25, the value is 72.61. This value is within the healthy range. It has increased from 37.98 (Mar 24) to 72.61, marking an increase of 34.63.
- For PBIT / Share (Rs.), as of Mar 25, the value is 42.17. This value is within the healthy range. It has increased from 8.37 (Mar 24) to 42.17, marking an increase of 33.80.
- For PBT / Share (Rs.), as of Mar 25, the value is 41.93. This value is within the healthy range. It has increased from 7.97 (Mar 24) to 41.93, marking an increase of 33.96.
- For Net Profit / Share (Rs.), as of Mar 25, the value is 33.74. This value is within the healthy range. It has increased from 3.54 (Mar 24) to 33.74, marking an increase of 30.20.
- For NP After MI And SOA / Share (Rs.), as of Mar 25, the value is 33.74. This value is within the healthy range. It has increased from 3.53 (Mar 24) to 33.74, marking an increase of 30.21.
- For PBDIT Margin (%), as of Mar 25, the value is 15.16. This value is within the healthy range. It has increased from 10.83 (Mar 24) to 15.16, marking an increase of 4.33.
- For PBIT Margin (%), as of Mar 25, the value is 8.80. This value is below the healthy minimum of 10. It has increased from 2.38 (Mar 24) to 8.80, marking an increase of 6.42.
- For PBT Margin (%), as of Mar 25, the value is 8.75. This value is below the healthy minimum of 10. It has increased from 2.27 (Mar 24) to 8.75, marking an increase of 6.48.
- For Net Profit Margin (%), as of Mar 25, the value is 7.04. This value is within the healthy range. It has increased from 1.00 (Mar 24) to 7.04, marking an increase of 6.04.
- For NP After MI And SOA Margin (%), as of Mar 25, the value is 7.04. This value is below the healthy minimum of 8. It has increased from 1.00 (Mar 24) to 7.04, marking an increase of 6.04.
- For Return on Networth / Equity (%), as of Mar 25, the value is 12.17. This value is below the healthy minimum of 15. It has increased from 1.42 (Mar 24) to 12.17, marking an increase of 10.75.
- For Return on Capital Employeed (%), as of Mar 25, the value is 13.88. This value is within the healthy range. It has increased from 3.07 (Mar 24) to 13.88, marking an increase of 10.81.
- For Return On Assets (%), as of Mar 25, the value is 6.44. This value is within the healthy range. It has increased from 0.78 (Mar 24) to 6.44, marking an increase of 5.66.
- For Total Debt / Equity (X), as of Mar 25, the value is 0.00. This value is within the healthy range. There is no change compared to the previous period (Mar 24) which recorded 0.00.
- For Asset Turnover Ratio (%), as of Mar 25, the value is 0.98. It has increased from 0.75 (Mar 24) to 0.98, marking an increase of 0.23.
- For Current Ratio (X), as of Mar 25, the value is 1.81. This value is within the healthy range. It has decreased from 1.86 (Mar 24) to 1.81, marking a decrease of 0.05.
- For Quick Ratio (X), as of Mar 25, the value is 1.32. This value is within the healthy range. It has increased from 1.23 (Mar 24) to 1.32, marking an increase of 0.09.
- For Inventory Turnover Ratio (X), as of Mar 25, the value is 4.40. This value is within the healthy range. It has increased from 1.40 (Mar 24) to 4.40, marking an increase of 3.00.
- For Dividend Payout Ratio (NP) (%), as of Mar 25, the value is 18.16. This value is below the healthy minimum of 20. It has decreased from 85.75 (Mar 24) to 18.16, marking a decrease of 67.59.
- For Dividend Payout Ratio (CP) (%), as of Mar 25, the value is 9.54. This value is below the healthy minimum of 20. It has increased from 9.14 (Mar 24) to 9.54, marking an increase of 0.40.
- For Earning Retention Ratio (%), as of Mar 25, the value is 81.84. This value exceeds the healthy maximum of 70. It has increased from 14.25 (Mar 24) to 81.84, marking an increase of 67.59.
- For Cash Earning Retention Ratio (%), as of Mar 25, the value is 90.46. This value exceeds the healthy maximum of 70. It has decreased from 90.86 (Mar 24) to 90.46, marking a decrease of 0.40.
- For Interest Coverage Ratio (X), as of Mar 25, the value is 311.10. This value is within the healthy range. It has increased from 94.68 (Mar 24) to 311.10, marking an increase of 216.42.
- For Interest Coverage Ratio (Post Tax) (X), as of Mar 25, the value is 145.56. This value is within the healthy range. It has increased from 9.82 (Mar 24) to 145.56, marking an increase of 135.74.
- For Enterprise Value (Cr.), as of Mar 25, the value is 4,929.40. It has increased from 2,811.46 (Mar 24) to 4,929.40, marking an increase of 2,117.94.
- For EV / Net Operating Revenue (X), as of Mar 25, the value is 1.14. This value is within the healthy range. It has increased from 0.88 (Mar 24) to 1.14, marking an increase of 0.26.
- For EV / EBITDA (X), as of Mar 25, the value is 7.52. This value is within the healthy range. It has decreased from 8.21 (Mar 24) to 7.52, marking a decrease of 0.69.
- For MarketCap / Net Operating Revenue (X), as of Mar 25, the value is 1.19. This value is within the healthy range. It has increased from 0.91 (Mar 24) to 1.19, marking an increase of 0.28.
- For Retention Ratios (%), as of Mar 25, the value is 81.83. This value exceeds the healthy maximum of 70. It has increased from 14.24 (Mar 24) to 81.83, marking an increase of 67.59.
- For Price / BV (X), as of Mar 25, the value is 2.06. This value is within the healthy range. It has increased from 1.29 (Mar 24) to 2.06, marking an increase of 0.77.
- For Price / Net Operating Revenue (X), as of Mar 25, the value is 1.19. This value is within the healthy range. It has increased from 0.91 (Mar 24) to 1.19, marking an increase of 0.28.
- For EarningsYield, as of Mar 25, the value is 0.05. This value is below the healthy minimum of 5. It has increased from 0.01 (Mar 24) to 0.05, marking an increase of 0.04.
Overall, while many metrics show healthy performance, any figures highlighted in red or significant downward trends warrant further investigation.
Strength and Weakness
| Strength | Weakness |
|---|---|
|
|
Stock Analysis
- Considering all of the following key financial indicators, prospective investors are encouraged to conduct thorough research and seek professional guidance before considering any investment in Sharda Cropchem Ltd:
- Net Profit Margin: 7.04%
- Net Profit Margin: This metric indicates the percentage of profit a company makes from its total revenue. A higher net profit margin is generally desirable as it reflects better profitability.
- ROCE: 13.88% (Industry Average ROCE: 15.21%)
- ROCE (Return on Capital Employed): ROCE measures a company's profitability and the efficiency with which its capital is employed. A higher ROCE indicates efficient use of capital.
- ROE%: 12.17% (Industry Average ROE: 19.87%)
- ROE (Return on Equity): ROE measures a company's profitability relative to shareholders' equity. A higher ROE indicates efficient use of shareholders' funds.
- Interest Coverage Ratio (Post Tax): 145.56
- Interest Coverage Ratio: The interest coverage ratio measures a company's ability to cover its interest payments on outstanding debt. A ratio greater than 2 is generally considered healthy as it indicates the company can meet its interest obligations comfortably.
- Quick Ratio: 1.32
- Quick Ratio: The quick ratio assesses a company's ability to cover its short-term liabilities with its most liquid assets. A ratio higher than 1 suggests the company can meet its short-term obligations without relying heavily on inventory.
- Stock P/E: 16.8 (Industry average Stock P/E: 32.39)
- Stock P/E (Price-to-Earnings) Ratio: The P/E ratio compares a company's current share price to its earnings per share. A lower P/E ratio relative to industry peers or historical values may indicate that the stock is undervalued.
- Total Debt / Equity: 0
- Total Debt / Equity: This ratio measures a company's financial leverage by comparing its total debt to its total equity. A lower ratio indicates lower financial risk and greater financial stability.
Stock Rating: - Net Profit Margin: 7.04%
About the Company - Qualitative Analysis
| INDUSTRY | ADDRESS | CONTACT |
|---|---|---|
| Agro Chemicals/Pesticides | Prime Business Park, Dashrathlal Joshi Road, Mumbai Maharashtra 400056 | Contact not found |
| Management | |
|---|---|
| Name | Position Held |
| Mr. Ramprakash V Bubna | Chairman & Managing Director |
| Mrs. Sharda R Bubna | Whole Time Director |
| Mr. Ashish R Bubna | Whole Time Director |
| Mr. Manish R Bubna | Whole Time Director |
| Ms. Sonal Desai | Independent Director |
| Mr. H S Upendra Kamath | Independent Director |
| Mr. Vinod Kathuria | Independent Director |
| Mr. Shalin Divatia | Independent Director |
FAQ
What is the intrinsic value of Sharda Cropchem Ltd?
Sharda Cropchem Ltd's intrinsic value (as of 07 January 2026) is ₹508.33 which is 39.41% lower the current market price of ₹839.00, indicating overvalued. Calculated using the PE ratio method, this valuation considers the company's ₹7,569 Cr. market cap, FY2025-2026 high/low of ₹1,181/440, reserves of ₹2,585 Cr, and liabilities of ₹4,903 Cr.
What is the Market Cap of Sharda Cropchem Ltd?
The Market Cap of Sharda Cropchem Ltd is 7,569 Cr..
What is the current Stock Price of Sharda Cropchem Ltd as on 07 January 2026?
The current stock price of Sharda Cropchem Ltd as on 07 January 2026 is ₹839.
What is the High / Low of Sharda Cropchem Ltd stocks in FY 2025-2026?
In FY 2025-2026, the High / Low of Sharda Cropchem Ltd stocks is ₹1,181/440.
What is the Stock P/E of Sharda Cropchem Ltd?
The Stock P/E of Sharda Cropchem Ltd is 16.8.
What is the Book Value of Sharda Cropchem Ltd?
The Book Value of Sharda Cropchem Ltd is 297.
What is the Dividend Yield of Sharda Cropchem Ltd?
The Dividend Yield of Sharda Cropchem Ltd is 1.07 %.
What is the ROCE of Sharda Cropchem Ltd?
The ROCE of Sharda Cropchem Ltd is 16.5 %.
What is the ROE of Sharda Cropchem Ltd?
The ROE of Sharda Cropchem Ltd is 12.6 %.
What is the Face Value of Sharda Cropchem Ltd?
The Face Value of Sharda Cropchem Ltd is 10.0.